SCHEMBL4474955

SCHEMBL4474955

CN(CCN1CCC(OC(=O)N(c2ccccc2-c2ccccc2)N(C(=O)O)c2ccccc2-c2ccccc2)CC1)C(=O)c1cccc(C(=O)NCCNCc2ccco2)c1

nearest known ligand 0.40

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
CHRM2 P08172 1/20 0.40
CHRM3 P20309 6/20 0.37
ADRB2 P07550 3/20 0.37
HTR7 P34969 2/20 0.37
HTR1A P08908 1/20 0.37
SLC5A7 Q9GZV3 1/20 0.36
DRD2 P14416 1/20 0.35
CARM1 Q86X55 1/20 0.35
PRMT6 Q96LA8 1/20 0.35
TSHR P16473 2/20 0.35
MAPK1 P28482 2/20 0.35
ALDH1A1 P00352 3/20 0.34
HPGD P15428 1/20 0.34
RECQL P46063 1/20 0.34
CYP3A4 P08684 1/20 0.34
CYP2C9 P11712 1/20 0.34
CYP2C19 P33261 1/20 0.34
SMYD2 Q9NRG4 1/20 0.34
HSD17B10 Q99714 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4490830 0.89 CHRM2 (0.44) CHRM2CHRM3ADRB2HTR7HTR1A
SCHEMBL4472532 0.89 CHRM2 (0.41) CHRM2CHRM3ADRB2HTR7HTR1A
SCHEMBL4475841 0.89 CHRM2 (0.43) CHRM2CHRM3ADRB2HTR7HTR1A
SCHEMBL4491995 0.88 CHRM2 (0.41) CHRM2CHRM3ADRB2HTR7HTR1A
SCHEMBL4483079 0.88 CHRM3 (0.44) CHRM2CHRM3ADRB2HTR7HTR1A
SCHEMBL4479676 0.88 CARM1 (0.45) CHRM2CHRM3ADRB2HTR7HTR1A
SCHEMBL4493960 0.88 CHRM2 (0.42) CHRM2CHRM3ADRB2HTR7HTR1A
SCHEMBL4494191 0.87 CHRM2 (0.43) CHRM2CHRM3ADRB2HTR1ASLC5A7
SCHEMBL4493963 0.87 CHRM3 (0.45) CHRM2CHRM3ADRB2SLC5A7
SCHEMBL266793 0.87 CHRM2 (0.55) CHRM2CHRM3ADRB2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7632847-B2 Bronchodilators; treating chronic obstructive pulmonary disease or asthma; long duration of action; reduced side effects, such as dry-mouth and constipation; e.g. biphenyl-2-ylcarbamic acid 1-(2-(3-[3-(4-hydroxybenzylamino)propionylamino]benzoylamino)ethyl)piperidin-4-yl ester THERAVANCE, INC. (US) 2009-12-15 US disclosed